Mirzotamab, CAS 2229859-11-2

Product Description: Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC)[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.

CAS Number: 2229859-11-2

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: CD276/B7-H3

• Artikelnummer: MEXHY-P99740-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99740-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated